While G-CSF is the standard of care in SCN and effective in more than 90% of patients (15), GM-CSF therapy has more recently been advocated in SCN cases with infections and refractory G-CSF response due to G-CSF receptor deficiency (16, 17). This evidence concerns the gene CSF3 and severe congenital neutropenia.